About this trial

This study will compare different combinations of fertility signs (cervical mucus (CM), luteinizing hormone \[LH\], pregnanediol glucuronide \[PDG\], and basal body temperature \[BBT\]) to determine which are most reliable for identifying ovulation and luteal phase length. Thirty existing Premom App users will track daily observations for three menstrual cycles. Participants will record mucus, perform urine tests, upload test strip photos to the Premom App, and measure BBT. Both participant readings and AI-assisted app readings will be analyzed. The main goal is to find which marker pairings give the most accurate picture of ovulation timing and luteal phase length. Secondary goals include understanding ease of use, the number of tests required, and whether the app improves accuracy.

Eligibility criteria

Qualifiers

Female, aged 16 to 45

Natural menstrual cycles equal or less than 35 days

Off hormonal contraception for more than 3 months

Current user of the Premom App

Disqualifiers

Pregnant or breastfeeding

Current hormonal therapy or contraception

Known anovulatory disorders, e.g., Polycystic Ovary Syndrome, hypothalamic amenorrhea.

Very irregular or absent cycles

Trial design

Treatments tested in this trial

  • Premom App-Assisted Fertility Tracking

Treatment groups

30 Participants
are divided into 1 treatment group

Locations

1
St. Laurent Ideal ClinicK1G 3V4, OttawaOntario, Canada

Sponsors and collaborators

Bruyère Health Research Institute.

Lead sponsor